Early clearance of Mycobacterium tuberculosis: A new frontier in prevention

Immunology

Volumn 141, Issue 4, 2014, Pages 506-513

  Verrall, Ayesha J ^a   G Netea, Mihai ^b   Alisjahbana, Bachti ^c   Hill, Philip C ^a   van Crevel, Reinout ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c PADJADJARAN UNIVERSITY   (Indonesia)

Author keywords

Early clearance; Innate immunity; Mycobacterium tuberculosis

Indexed keywords

BCG VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; VITAMIN D;

ADAPTIVE IMMUNITY; BACTERIAL CLEARANCE; BCG VACCINATION; FOLLOW UP; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; LATENT TUBERCULOSIS; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; PATTERN RECOGNITION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUBERCULIN TEST; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ANIMALS; BACTERIAL LOAD; COINFECTION; CYTOKINES; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; MACROPHAGES, ALVEOLAR; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; PHAGOCYTOSIS; PHENOTYPE; T-LYMPHOCYTE SUBSETS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VITAMIN D DEFICIENCY;

EID: 84895787342     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12223     Document Type: Review

References (100)

1. WHO. Tuberculosis [Internet]. WHO. Geneva: World Health Organization. Available from: http://www.who.int/mediacentre/factsheets/fs104/en/ [accessed on 12 March 2013]
2. Tameris MD, Hatherill M, Landry BS et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381:1021-8.
3. Dheda K, Schwander SK, Zhu B-D, van Zyl-Smit RN, Zhang Y. The immunology of tuberculosis: from bench to bedside. Respirology 2010; 15:433-50.
4. Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb) 2012; 92(Suppl. 1): S6-13.
5. Israel HL, Hetherington HW, Ord JG. A study of tuberculosis among students of nursing. JAMA 1941; 117:839-44.
6. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:359-68.
7. Rieder HL. Epidemiologic basis of tuberculosis control, 1st edn. Paris: International Union Against Tuberculosis and Lung Disease (IUATLD), 1999.
8. Houk VN, Baker JH, Sorensen K, Kent DC. The epidemiology of tuberculosis infection in a closed environment. Arch Environ Health 1968; 16:26-35.
9. Lurie MB. Experimental epidemiology of tuberculosis. J Exp Med 1944; 79:573-89.
10. Cobat A, Barrera LF, Henao H, Arbelaez P, Abel L, García F, Schurr E, Alcaïs A. Tuberculin skin test reactivity is dependent on host genetic background in Colombian tuberculosis household contacts. Clin Infect Dis 2012; 54:968-71.
11. Cobat A, Gallant CJ, Simkin L et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J Exp Med 2009; 206:2583-91.
12. Thye T, Browne EN, Chinbuah MA et al. IL10 haplotype associated with tuberculin skin test response but not with pulmonary TB. PLoS ONE 2009; 4:e5420.
13. Zembrzuski VM, Basta PC, Callegari-Jacques SM, Santos RV, Coimbra CE, Salzano FM, Hutz MH. Cytokine genes are associated with tuberculin skin test response in a native Brazilian population. Tuberculosis (Edinb) 2010; 90:44-9.
14. van Crevel R, van der Ven-Jongekrijg J, Netea MG, de Lange W, Kullberg BJ, van der Meer JW. Disease-specific ex vivo stimulation of whole blood for cytokine production: applications in the study of tuberculosis. J Immunol Methods 1999; 222:145-53.
15. The Lübeck catastrophy: a general review. BMJ 1931; 1:986.
16. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006; 174:831-9.
17. Zanetti C, Peracchi M, Zorzi D, Fiorio S, Fallico L, Palu G. Outbreak of transient conversions of the QuantiFERON-TB gold in-tube test in laboratory health care worker screenings. Clin Vaccine Immunol 2012; 19:954-60.
18. Nardell EA, Wallis RS. Here today-gone tomorrow: the case for transient acute tuberculosis infection. Am J Respir Crit Care Med 2006; 174:734-5.
19. Adetifa IM, Ota MOC, Jeffries DJ et al. Interferon γ ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial. Am J Respir Crit Care Med 2013; 187:439-45.
20. Li Y, Wang Y, Liu X. The role of airway epithelial cells in response to mycobacteria infection. Clin Dev Immunol 2012; 2012:791392.
21. Lurie MB, Zappasodi P, Dannenberg AM, Weiss GH. On the mechanism of genetic resistance to tuberculosis and its mode of inheritance. Am J Hum Genet 1952; 4:302-14.
22. Davis JM, Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 2009; 136:37-49.
23. Gammack D, Doering CR, Kirschner DE. Macrophage response to Mycobacterium tuberculosis infection. J Math Biol 2004; 48:218-42.
24. Day J, Friedman A, Schlesinger LS. Modeling the immune rheostat of macrophages in the lung in response to infection. Proc Natl Acad Sci U S A 2009; 106:11246-51.
25. Blumenthal RL, Campbell DE, Hwang P, DeKruyff RH, Frankel LR, Umetsu DT. Human alveolar macrophages induce functional inactivation in antigen-specific CD4 T cells. J Allergy Clin Immunol 2001; 107:258-64.
26. Flynn JL, Chan J, Lin PL. Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunol 2011; 4:271-8.
27. Thoma-Uszynski S, Stenger S, Takeuchi O et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001; 291:1544-7.
28. Underhill DM, Ozinsky A, Smith KD, Aderem A. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci U S A 1999; 96:14459-63.
29. Jones BW, Means TK, Heldwein KA, Keen MA, Hill PJ, Belisle JT, Fenton MJ. Different Toll-like receptor agonists induce distinct macrophage responses. J Leukoc Biol 2001; 69:1036-44.
30. Cervantes JL, Weinerman B, Basole C, Salazar JC. TLR8: the forgotten relative revindicated. Cell Mol Immunol 2012; 9:434-8.
31. Gantier MP, Irving AT, Kaparakis-Liaskos M et al. Genetic modulation of TLR8 response following bacterial phagocytosis. Hum Mutat 2010; 31:1069-79.
32. Davila S, Hibberd ML, Hari Dass R et al. Genetic association and expression studies indicate a role of toll-like receptor 8 in pulmonary tuberculosis. PLoS Genet 2008; 4:e1000218.
33. Juárez E, Carranza C, Hernández-Sánchez F, León-Contreras JC, Hernández-Pando R, Escobedo D, Torres M, Sada E. NOD2 enhances the innate response of alveolar macrophages to Mycobacterium tuberculosis in humans. Eur J Immunol 2012; 42:880-9.
34. Austin CM, Ma X, Graviss EA. Common nonsynonymous polymorphisms in the NOD2 gene are associated with resistance or susceptibility to tuberculosis disease in African Americans. J Infect Dis 2008; 197:1713-6.
35. Möller M, Nebel A, Kwiatkowski R, Van Helden PD, Hoal EG, Schreiber S. Host susceptibility to tuberculosis: CARD15 polymorphisms in a South African population. Mol Cell Probes 2007; 21:148-51.
36. Stockton JC, Howson JMM, Awomoyi AA, McAdam KP, Blackwell JM, Newport MJ. Polymorphism in NOD2, Crohn's disease, and susceptibility to pulmonary tuberculosis. FEMS Immunol Med Microbiol 2004; 41:157-60.
37. Dorhoi A, Nouailles G, Jörg S et al. Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis. Eur J Immunol 2011; 42:374-84.
38. Pontillo A, Carvalho MS, Kamada AJ, Moura R, Schindler HC, Duarte AJ, Crovella S. Susceptibility to Mycobacterium tuberculosis infection in HIV-positive patients is associated with CARD8 genetic variant. J Acquir Immune Defic Syndr 2013; 63:147-51.
39. Tailleux L, Pham-Thi N, Bergeron-Lafaurie A et al. DC-SIGN induction in alveolar macrophages defines privileged target host cells for mycobacteria in patients with tuberculosis. PLoS Med 2005; 2:e381.
40. Miyake Y, Toyonaga K, Mori D et al. C-type lectin MCL is an FcRg-coupled receptor that mediates the adjuvanticity of mycobacterial cord factor. Immunity 2013; 38:1050-62.
41. Welin A, Raffetseder J, Eklund D, Stendahl O, Lerm M. Importance of phagosomal functionality for growth restriction of Mycobacterium tuberculosis in primary human macrophages. J Innate Immun 2011; 3:508-18.
42. Flesch IE, Kaufmann SH. Activation of tuberculostatic macrophage functions by γ interferon, interleukin-4, and tumor necrosis factor. Infect Immun 1990; 58:2675-7.
43. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 1988; 141:2407-12.
44. Denis M. Killing of Mycobacterium tuberculosis within human monocytes: activation by cytokines and calcitriol. Clin Exp Immunol 1991; 84:200-6.
45. Kang PB, Azad AK, Torrelles JB, Kaufman TM, Beharka A, Tibesar E, DesJardin LE, Schlesinger LS. The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J Exp Med 2005; 202:987-99.
46. Rajaram MVS, Brooks MN, Morris JD, Torrelles JB, Azad AK, Schlesinger LS. Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor γ linking mannose receptor recognition to regulation of immune responses. J Immunol 2010; 185:929-42.
47. Torrelles JB, Azad AK, Schlesinger LS. Fine discrimination in the recognition of individual species of phosphatidyl-myo-inositol mannosides from Mycobacterium tuberculosis by C-type lectin pattern recognition receptors. J Immunol 2006; 177:1805-16.
48. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004; 119:753-66.
49. Songane M, Kleinnijenhuis J, Alisjahbana B et al. Polymorphisms in autophagy genes and susceptibility to tuberculosis. Carvalho LH, editor. PLoS ONE 2012; 7:e41618.
50. Xu Y, Jagannath C, Liu X-D, Sharafkhaneh A, Kolodziejska KE, Eissa NT. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 2007; 27:135-44.
51. Sow FB, Florence WC, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP. Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis. J Leukoc Biol 2007; 82:934-45.
52. Martineau AR, Wilkinson KA, Newton SM et al. IFN-γ- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol 2007; 178:7190-8.
53. Martin CJ, Booty MG, Rosebrock TR et al. Efferocytosis is an innate antibacterial mechanism. Cell Host Microbe 2012; 12:289-300.
54. Divangahi M, Chen M, Gan H et al. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat Immunol 2009; 10:899-906.
55. Tobin DM, Roca FJ, Oh SF et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012; 148:434-46.
56. Martineau AR, Newton SM, Wilkinson KA et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 2007; 117:1988-94.
57. Lowe DM, Redford PS, Wilkinson RJ, O'Garra A, Martineau AR. Neutrophils in tuberculosis: friend or foe? Trends Immunol 2012; 33:14-25.
58. Sugawara I, Udagawa T, Yamada H. Rat neutrophils prevent the development of tuberculosis. Infect Immun 2004; 72:1804-6.
59. Pedrosa J, Saunders BM, Appelberg R, Orme IM, Silva MT, Cooper AM. Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice. Infect Immun 2000; 68:577-83.
60. Petrofsky M, Bermudez LE. Neutrophils from Mycobacterium avium-infected mice produce TNF-α, IL-12, and IL-1βand have a putative role in early host response. Clin Immunol 1999; 91:354-8.
61. Kisich KO, Higgins M, Diamond G, Heifets L. Tumor necrosis factor α stimulates killing of Mycobacterium tuberculosis by human neutrophils. Infect Immun 2002; 70:4591-9.
62. Vankayalapati R, Wizel B, Weis SE et al. The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol 2002; 168:3451-7.
63. Brill KJ, Li Q, Larkin R, Canaday DH, Kaplan DR, Boom WH, Silver RF. Human natural killer cells mediate killing of intracellular Mycobacterium tuberculosis H37Rv via granule-independent mechanisms. Infect Immun 2001; 69:1755-65.
64. Dhiman R, Indramohan M, Barnes PF, Nayak RC, Paidipally P, Rao LV, Vankayalapati R. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol 2009; 183:6639-45.
65. Junqueira-Kipnis AP, Kipnis A, Jamieson A, Juarrero MG, Diefenbach A, Raulet DH, Turner J, Orme IM. NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection. J Immunol 2003; 171:6039-45.
66. Sugawara I, Yamada H, Mizuno S, Li CY, Nakayama T, Taniguchi M. Mycobacterial infection in natural killer T cell knockout mice. Tuberculosis (Edinb) 2002; 82:97-104.
67. Chua WJ, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, Hansen TH. Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection. Infect Immun 2012; 80:3256-67.
68. Meierovics A, Yankelevich W-JC, Cowley SC. MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. Proc Natl Acad Sci U S A 2013; 110:E3119-28.
69. Meraviglia S, El Daker S, Dieli F, Martini F, Martino A. γδ T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection. Clin Dev Immunol 2011; 2011: Article ID 587315.
70. Lawn SD, Butera ST, Shinnick TM. Tuberculosis unleashed: the impact of human immunodeficiency virus infection on the host granulomatous response to Mycobacterium tuberculosis. Microbes Infect 2002; 4:635-46.
71. Patel NR, Zhu J, Tachado SD, Zhang J, Wan Z, Saukkonen J, Koziel H. HIV impairs TNF-α mediated macrophage apoptotic response to Mycobacterium tuberculosis. J Immunol 2007; 179:6973-80.
72. Hasegawa A, Liu H, Ling B et al. The level of monocyte turnover predicts disease progression in the macaque model of AIDS. Blood 2009; 114:2917-25.
73. Blanchet FP, Moris A, Nikolic DS et al. Human immunodeficiency virus-1 inhibition of immunoamphisomes in dendritic cells impairs early innate and adaptive immune responses. Immunity 2010; 32:654-69.
74. Cameron PU, Handley AJ, Baylis DC, Solomon AE, Bernard N, Purcell DF, Lewin SR. Preferential infection of dendritic cells during human immunodeficiency virus type 1 infection of blood leukocytes. J Virol 2007; 81:2297-306.
75. Guerra C, Johal K, Morris D et al. Control of Mycobacterium tuberculosis growth by activated natural killer cells. Clin Exp Immunol 2012; 168:142-52.
76. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358:1687-93.
77. Houben RMGJ, Crampin AC, Ndhlovu R et al. Human immunodeficiency virus associated tuberculosis more often due to recent infection than reactivation of latent infection. Int J Tuberc Lung Dis 2011; 15:24-31.
78. Naranbhai V, Hill AV, Abdool Karim SS, Naidoo K, Abdool Karim Q, Warimwe GM, McShane H, Fletcher H. Blood monocyte-lymphocyte ratios identify adults at risk of incident tuberculosis amongst patients initiating antiretroviral therapy. J Infect Dis 2013; doi: 10.1093/infdis/jit494.
79. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311:1770-3.
80. Campbell GR, Spector SA. Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog 2012; 8:e1002689.
81. Martineau AR, Wilkinson RJ, Wilkinson KA et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 2007; 176:208-13.
82. Wilkinson RJ, Llewelyn M, Toossi Z et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000; 355:618-21.
83. Ralph AP, Lucas RM, Norval M. Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis. Lancet Infect Dis 2013; 13:77-88.
84. Arnedo-Pena A, Juan-Cerdán JV, Romeu-Garcia A et al. Latent tuberculosis infection, tuberculin skin test and vitamin D status in contacts of tuberculosis patients: a cross-sectional and case-control study. BMC Infect Dis 2011; 11:349.
85. Ganmaa D, Giovannucci E, Bloom BR et al. Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebo-controlled feasibility trial. Am J Clin Nutr 2012; 96:391-6.
86. Kagina BM, Abel B, Scriba TJ et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 2010; 182:1073-9.
87. Braden CR, Morlock GP, Woodley CL et al. Simultaneous infection with multiple strains of Mycobacterium tuberculosis. Clin Infect Dis 2001; 33:e42-7.
88. van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, Beyers N, van Helden PD. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341:1174-9.
89. Verver S, Warren RM, Beyers N et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171:1430-5.
90. Hill PC, Ota MOC. Tuberculosis case-contact research in endemic tropical settings: design, conduct, and relevance to other infectious diseases. Lancet Infect Dis 2010; 10:723-32.
91. Sutherland JS, Hill PC, Adetifa IM et al. Identification of probable early-onset biomarkers for tuberculosis disease progression. PLoS ONE 2011; 6:e25230.
92. Thuong NT, Dunstan SJ, Chau TT et al. Identification of tuberculosis susceptibility genes with human macrophage gene expression profiles. PLoS Pathog 2008; 4:e1000229.
93. Schwander S, Dheda K. Human lung immunity against Mycobacterium tuberculosis. Am J Respir Crit Care Med 2011; 183:696-707.
94. Stein CM. Genetic epidemiology of tuberculosis susceptibility: impact of study design. PLoS Pathog 2011; 7:e1001189.
95. Wilkinson RJ. Human genetic susceptibility to tuberculosis: time for a bottom-up approach? J Infect Dis 2012; 205:525-7.
96. Amberson JB, Riggins H. Tuberculosis among student nurses: a five year study at Bellevue hospital. Ann Intern Med 1936:156-165.
97. Lutong L, Bei Z. Association of prevalence of tuberculin reactions with closeness of contact among household contacts of new smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2000; 4:275-7.
98. Lienhardt C, Fielding K, Sillah J et al. Risk factors for tuberculosis infection in Sub-Saharan Africa. Am J Respir Crit Care Med 2003; 168:448-55.
99. Hill PC, Brookes RH, Fox A et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 2004; 38:966-73.
100. Muecke C, Isler M, Menzies D, Allard R, Tannenbaum TN, Brassard P. The use of environmental factors as adjuncts to traditional tuberculosis contact investigation. Int J Tuberc Lung Dis 2006; 10:530-5.